98 related articles for article (PubMed ID: 9853453)
1. HAART and host: balancing the response to HIV-1. Highly active antiretroviral therapy.
Morris K
Lancet; 1998 Nov; 352(9141):1686. PubMed ID: 9853453
[No Abstract] [Full Text] [Related]
2. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P
Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection.
Martinez-Mariño B; Ashlock BM; Shiboski S; Hecht FM; Levy JA
J Clin Immunol; 2004 Mar; 24(2):135-44. PubMed ID: 15024180
[TBL] [Abstract][Full Text] [Related]
4. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of HIV infection: combination drug therapy effective, immunotherapy still experimental].
Dtsch Med Wochenschr; 1997 Apr; 122(15):A32. PubMed ID: 9147936
[No Abstract] [Full Text] [Related]
6. Prospect of IL-2, IL-7, IL-15 and IL-21 for HIV immune-based therapy.
Diallo M; Zheng Y; Chen X; He Y; Zhou H; Chen Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1037-45. PubMed ID: 22169717
[TBL] [Abstract][Full Text] [Related]
7. Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells.
Tsoukas CM; Turner HM; Hatzakis GE; Blake GP; Goodhew JE; Kilby DL; Kovacs CM; Luetkehoelter JR; Routy JP; Walmsley SL; Bernard NF
AIDS Res Hum Retroviruses; 2001 Jul; 17(10):887-900. PubMed ID: 11461675
[TBL] [Abstract][Full Text] [Related]
8. IL-2 plus HAART reduces HIV in immune system "hiding places".
WORLD; 1998 Dec; (No 92):7. PubMed ID: 11365976
[TBL] [Abstract][Full Text] [Related]
9. [Moxibustion combined with highly active antiretroviral therapy for CD
Liu Z; Deng X; Mo J; Jiang F; Wen B; Zhang Y; Pang J
Zhongguo Zhen Jiu; 2018 Jan; 38(1):3-6. PubMed ID: 29354928
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Dybul M; Hidalgo B; Chun TW; Belson M; Migueles SA; Justement JS; Herpin B; Perry C; Hallahan CW; Davey RT; Metcalf JA; Connors M; Fauci AS
J Infect Dis; 2002 Jan; 185(1):61-8. PubMed ID: 11756982
[TBL] [Abstract][Full Text] [Related]
11. New strategies to combat HIV: augmenting antiviral immunity.
Smith KA; Boyle BA
AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
[No Abstract] [Full Text] [Related]
12. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.
Mitsuyasu R
J Infect Dis; 2002 May; 185 Suppl 2():S115-22. PubMed ID: 12001032
[TBL] [Abstract][Full Text] [Related]
13. IL-2 taken to HAART.
Gilden D
GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
[TBL] [Abstract][Full Text] [Related]
14. IL-2 immunotherapy does not benefit patients taking antiretrovirals.
AIDS Patient Care STDS; 2009 Mar; 23(3):221-2. PubMed ID: 19866543
[No Abstract] [Full Text] [Related]
15. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
16. Encouraging data on quality of life reported for IL-2 therapy.
AIDS Patient Care STDS; 1996 Oct; 10(5):314-5. PubMed ID: 11361537
[No Abstract] [Full Text] [Related]
17. Immunological effects of antiretroviral and immune therapies for HIV.
Kelleher AD; Al-Harthi L; Landay AL
AIDS; 1997; 11 Suppl A():S149-55. PubMed ID: 9451979
[No Abstract] [Full Text] [Related]
18. [Approaches to pathogenetic immunotherapy of HIV-infections].
Nikol'skiĭ IS; Iurchenko VD
Lik Sprava; 2002; (7):7-14. PubMed ID: 12587295
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
Davey RT; Bhat N; Yoder C; Chun TW; Metcalf JA; Dewar R; Natarajan V; Lempicki RA; Adelsberger JW; Miller KD; Kovacs JA; Polis MA; Walker RE; Falloon J; Masur H; Gee D; Baseler M; Dimitrov DS; Fauci AS; Lane HC
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15109-14. PubMed ID: 10611346
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 treatment for HIV infection.
Blankson J; Siliciano RF
JAMA; 2000 Jul; 284(2):236-8. PubMed ID: 10889599
[No Abstract] [Full Text] [Related]
[Next] [New Search]
